Minerva CEO granted 1.69M stock options at $4.68

Minerva Neurosciences CEO Remy Luthringer received a new stock option grant.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Minerva Neurosciences CEO Remy Luthringer received a new stock option grant. The award covers 1,690,700 options to buy Minerva common stock at an exercise price of $4.68 per share. The option vests 25% on June 3, 2027, with the remainder vesting in equal quarterly installments over the following three years, and expires on June 2, 2036.

Insider Trade Summary

Grant/Award: 1,690,700 shares

Grant/Award 1 txn

Insider Luthringer Remy

Role CEO

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	1,690,700	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 1,690,700 contracts (Direct)

Footnotes (1)

F1. The option vests 25% on June 3, 2027 and then in equal quarterly installments over 3 years thereafter.

Key Figures

Option grant size: 1,690,700 options Exercise price: $4.68 per share Post-grant option holdings: 1,690,700 options +3 more

6 metrics

Option grant size 1,690,700 options Employee stock option grant to CEO Remy Luthringer

Exercise price $4.68 per share Exercise price of employee stock option grant

Post-grant option holdings 1,690,700 options Total options held directly after the transaction

Initial vesting date June 3, 2027 25% of the option grant vests on this date

Vesting schedule remainder Equal quarterly over 3 years Remaining 75% vests quarterly after June 3, 2027

Option expiration date June 2, 2036 Expiration of employee stock option grant

Key Terms

Employee Stock Option (right to buy), exercise price, vesting, expiration date

4 terms

Employee Stock Option (right to buy) financial

"security_title: Employee Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 4.6800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The option vests 25% on June 3, 2027 and then in equal quarterly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: 2036-06-02T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock option grant did Minerva Neurosciences (NERV) CEO receive?

Minerva Neurosciences CEO Remy Luthringer received an option to buy 1,690,700 shares of common stock at an exercise price of $4.68 per share as part of his compensation package.

How do the new NERV CEO stock options vest?

The option vests 25% on June 3, 2027, then the remaining 75% vests in equal quarterly installments over the next three years, tying the CEO’s potential benefit to sustained service and long-term performance.

When do the newly granted Minerva Neurosciences CEO options expire?

The stock options granted to Minerva Neurosciences CEO Remy Luthringer expire on June 2, 2036, giving a long window during which he can choose to exercise them if the company’s share price exceeds the $4.68 exercise price.

Is the Minerva Neurosciences CEO option grant an open-market stock purchase?

No. The Form 4 shows a compensation-related grant of employee stock options with code “A,” not an open-market stock purchase. The options were awarded at an exercise price of $4.68 and vest over several years.

How many Minerva Neurosciences options does the CEO hold after this grant?

After this transaction, CEO Remy Luthringer holds 1,690,700 employee stock options directly, each exercisable for one share of Minerva Neurosciences common stock at an exercise price of $4.68, subject to the vesting schedule and expiration date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/05/2026 - 06:00 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Luthringer Remy

(Last)

(First)

(Middle)

C/O MINERVA NEUROSCIENCES, INC.

1500 DISTRICT AVENUE

(Street)

BURLINGTON

MASSACHUSETTS

01803

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Minerva Neurosciences, Inc. [ NERV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (right to buy)	$4.68	06/03/2026		A		1,690,700		⁽¹⁾	06/02/2036	Common Stock	1,690,700	$0	1,690,700	D

Explanation of Responses:

1. The option vests 25% on June 3, 2027 and then in equal quarterly installments over 3 years thereafter.

	/s/ Frederick Ahlholm, Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR